Related Experiment Videos
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer
D G Pfister1, D Bajorin, R J Motzer
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract:
Fifteen patients with recurrent squamous cell head and neck cancer were treated with deoxyspergualin. There were no objective responses in 14 evaluable patients. The most common toxicity was reversible hypotension, which prompted dose reduction in nine patients. Deoxyspergualin is not recommended for the treatment of squamous cell head and neck cancer.
Insights
Deoxyspergualin showed no effectiveness in treating recurrent squamous cell head and neck cancer. The drug caused significant toxicity, primarily reversible hypotension, leading to dose reductions in most patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Recurrent squamous cell head and neck cancer presents a significant clinical challenge.
- Effective treatment options for recurrent disease are limited, necessitating exploration of novel therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and safety of deoxyspergualin in patients with recurrent squamous cell head and neck cancer.
Main Methods:
- A clinical trial involving fifteen patients with recurrent squamous cell head and neck cancer.
- Treatment administered was deoxyspergualin.
- Efficacy was assessed by objective response, and toxicity was closely monitored.
Main Results:
- No objective responses were observed in the 14 evaluable patients.
- The most frequent adverse event was reversible hypotension, occurring in nine patients.
- Hypotension frequently necessitated dose reduction.
Conclusions:
- Deoxyspergualin demonstrated a lack of efficacy in this patient cohort.
- The observed toxicity profile, particularly hypotension, limits its therapeutic potential.
- Deoxyspergualin is not recommended for treating recurrent squamous cell head and neck cancer.